Waldencast plc (WALD)
NASDAQ: WALD · Real-Time Price · USD
2.330
-0.100 (-4.12%)
Dec 5, 2025, 4:00 PM EST - Market closed
Waldencast Revenue
Waldencast had revenue of $132.27M in the half year ending June 30, 2025, with 20.98% growth. This brings the company's revenue in the last twelve months to $274.56M, up 14.22% year-over-year. In the year 2024, Waldencast had annual revenue of $273.87M with 25.55% growth.
Revenue (ttm)
$274.56M
Revenue Growth
+14.22%
P/S Ratio
0.96
Revenue / Employee
$819,582
Employees
335
Market Cap
287.57M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 273.87M | 55.73M | 25.55% |
| Dec 31, 2023 | 218.14M | 52.01M | 31.30% |
| Dec 31, 2022 | 166.13M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Berkshire Hathaway | 372.13B |
| JPMorgan Chase & Co. | 167.23B |
| Bank of America | 101.45B |
| Wells Fargo & Company | 79.07B |
| Morgan Stanley | 68.53B |
| American Express Company | 65.29B |
| HSBC Holdings | 57.98B |
| The Goldman Sachs Group | 57.34B |
WALD News
- 20 days ago - Obagi Medical Shares New Clinical Data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery Annual Meeting - GlobeNewsWire
- 22 days ago - Waldencast plc strengthens balance sheet position with the announcement of a trademark sale for Japan and refinancing of its credit facilities - GlobeNewsWire
- 24 days ago - Waldencast plc Provides Information Regarding Upcoming Earnings Release Dates - GlobeNewsWire
- 2 months ago - Obagi Medical Launches Nu-Cil® BioStim™ Scalp Serum - GlobeNewsWire
- 3 months ago - Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand - GlobeNewsWire
- 3 months ago - Waldencast Announces Strong Progress on Business Priorities for H1 2025 and Initiatives to Drive Transformation - GlobeNewsWire
- 3 months ago - Waldencast Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Benzinga
- 4 months ago - Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand - GlobeNewsWire